Genzyme acquires SangStat Medical

FRAMINGHAM (09/24/2003) - In a US$600-million deal set to close this month, Genzyme Corp. will acquire SangStat Medical Corp. A global biotechnology company focused on immunology, SangStat's pipeline complements Genzyme's work in immune-mediated diseases. The $22.50-per-share transaction amount represents an approximately 45-percent premium over the closing price of SangStat's shares on Aug. 1.

Join the newsletter!

Error: Please check your email address.

More about SangStat Medical

Show Comments